{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T05:27:22Z","timestamp":1787462842596,"version":"build-2736575974"},"reference-count":110,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2020,6,17]],"date-time":"2020-06-17T00:00:00Z","timestamp":1592352000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81273308"],"award-info":[{"award-number":["81273308"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Scand J Immunol"],"published-print":{"date-parts":[[2020,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Multiple myeloma (MM) is a haematological malignancy caused by malignant proliferation of plasma cells in bone marrow. In recent years, MM patients are commonly treated with chemotherapy, autologous stem cell transplantation, protease inhibitors, immunomodulatory drugs and monoclonal antibodies, however most patients eventually relapse. Therefore, more effective therapies are highly needed. Anti\u2010BCMA CAR\u2010T therapy, a novel and efficacious method for treating MM and relapsed\/refractory multiple myeloma (RRMM), has been designed and applied in clinics. The CAR\u2010T can specifically recognize the targeted molecule B cell maturation antigen (BCMA) and kill MM cells expressing BCMA and several clinical trials have revealed high response rates in the therapy. Herein, we summarize the developments, the current design and clinical trials, the side effects of anti\u2010BCMA CAR\u2010T therapy and comparison of it with other CAR\u2010T therapies.<\/jats:p>","DOI":"10.1111\/sji.12910","type":"journal-article","created":{"date-parts":[[2020,5,30]],"date-time":"2020-05-30T00:27:15Z","timestamp":1590798435000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Overview of anti\u2010BCMA CAR\u2010T immunotherapy for multiple myeloma and relapsed\/refractory multiple myeloma"],"prefix":"10.1111","volume":"92","author":[{"given":"Deming","family":"Feng","sequence":"first","affiliation":[{"name":"Department of Molecular and Cellular Pharmacology School of Pharmaceutical Science and Technology Tianjin University Tianjin China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1749-6789","authenticated-orcid":false,"given":"Jian","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Molecular and Cellular Pharmacology School of Pharmaceutical Science and Technology Tianjin University Tianjin China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,6,17]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00453"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2019.09.007"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.disamonth.2014.08.002"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-18-0551"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201607485"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-017-0373-2"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-017-0423-1"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-018-03592-9"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2019.01.010"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/biot.201700097"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1159\/000481946"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-017-0102-y"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0690-8"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2017.07.007"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.19361"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1615\/CritRevImmunol.v32.i4.10"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2017.1393668"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.3109\/08916934.2010.509122"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-2422"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1042\/BST20150280"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-0168"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers10090323"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1177\/0961203315608254"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737159.2018.1448269"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-04-711903"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2018.001"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817226"},{"key":"e_1_2_9_29_1","doi-asserted-by":"crossref","first-page":"4979","DOI":"10.1158\/1538-7445.AM2017-4979","article-title":"Development of KITE\u2010585: a fully human BCMA CAR T\u2010cell therapy for the treatment of multiple myeloma","volume":"77","author":"Adams GB","year":"2017","journal-title":"Cancer Res"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.TPS3103"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-113220"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.09.083"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.09.034"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-018-0672-7"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-691162"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-05-781351"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000703"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.09.267"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-018-0681-6"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.302"},{"key":"e_1_2_9_41_1","first-page":"1723","article-title":"Improved efficacy and safety of a dual\u2010target CAR\u2010T cell therapy targeting BCMA and CD38 for relapsed\/refractory multiple myeloma from a phase I study","volume":"49","author":"Li C","year":"2019","journal-title":"Eur J Immunol"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30115-2"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000050"},{"key":"e_1_2_9_44_1","doi-asserted-by":"crossref","first-page":"3759","DOI":"10.1158\/1538-7445.AM2017-3759","article-title":"PiggyBac\u2010manufactured anti\u2010BCMA Centyrin\u2010based CAR\u2010T therapeutic exhibits improved potency and durability","volume":"77","author":"Hermanson D","year":"2017","journal-title":"Cancer Res"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.2127.2127"},{"key":"e_1_2_9_46_1","first-page":"3068","article-title":"B\u2010cell maturation antigen (BCMA)\u2010pecific, centyrin (TM)\u2010based, PiggyBac (TM)\u2010Transposed CAR\u2010T memory stem cells are effective against p53(\u2010\/\u2010) and patient\u2010derived multiple myeloma tumors","volume":"130","author":"Mathur R","year":"2017","journal-title":"Blood"},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-111419"},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-116953"},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-113548"},{"key":"e_1_2_9_50_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-112786"},{"key":"e_1_2_9_51_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-119717"},{"key":"e_1_2_9_52_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-125372"},{"key":"e_1_2_9_53_1","first-page":"3067","article-title":"CD8+Anti\u2010BCMA mRNA CAR T\u2010cells effectively kill human multiple myeloma cells in vitro and in vivo","volume":"130","author":"Lin L","year":"2017","journal-title":"Blood"},{"key":"e_1_2_9_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.09.283"},{"key":"e_1_2_9_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.09.035"},{"key":"e_1_2_9_56_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-119227"},{"key":"e_1_2_9_57_1","first-page":"P165","article-title":"Robust, reproducible and highly scalable manufacturing of P\u2010BCMA\u2010ALLO1, an allogeneic CAR\u2010T stem cell memory product for multiple myeloma, from numerous healthy donors","volume":"7","author":"Cranert S","year":"2019","journal-title":"J IMMUNOTHER CANCER"},{"key":"e_1_2_9_58_1","first-page":"O7","article-title":"P\u2010BCMA\u2010ALLO1\u2010a nonviral, allogeneic anti\u2010BCMA CAR\u2010T therapy with potent antitumor function for the treatment of multiple myeloma","volume":"7","author":"Richter M","year":"2019","journal-title":"J IMMUNOTHER CANCER"},{"key":"e_1_2_9_59_1","first-page":"503","article-title":"Production of universal anti\u2010Bcma CAR\u2010T cells with reduced alloreactivity, but potent effector function for the treatment of multiple myeloma","volume":"130","author":"Wang XX","year":"2017","journal-title":"Blood"},{"key":"e_1_2_9_60_1","first-page":"39","article-title":"Cloning and expression of CD19, a human B\u2010cell marker in NIH\u20103T3 cell line","volume":"7","author":"Abbasi\u2010Kenarsari H","year":"2015","journal-title":"Avicenna J Med Biotechnol"},{"key":"e_1_2_9_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2015.06.001"},{"issue":"889","key":"e_1_2_9_62_1","first-page":"e6","article-title":"CD19 controls Toll\u2010like receptor 9 responses in human B cells","volume":"137","author":"Morbach H","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"e_1_2_9_63_1","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.120505"},{"key":"e_1_2_9_64_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10948-w"},{"key":"e_1_2_9_65_1","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2016.1209112"},{"key":"e_1_2_9_66_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-10-646810"},{"key":"e_1_2_9_67_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V126.23.115.115"},{"key":"e_1_2_9_68_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-04-778423"},{"key":"e_1_2_9_69_1","doi-asserted-by":"publisher","DOI":"10.1631\/jzus.B1900351"},{"key":"e_1_2_9_70_1","first-page":"3055","article-title":"The new immunoreceptor SLAMF3 promotes aggressive biological and clinical characteristics in multiple myeloma","volume":"130","author":"Ishibashi M","year":"2017","journal-title":"Blood"},{"key":"e_1_2_9_71_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-14619-z"},{"key":"e_1_2_9_72_1","first-page":"3142","article-title":"Chimeric Antigen Receptor (CAR) T cells specific for CD229: a potentially curative approach for multiple myeloma","volume":"130","author":"Radhakrishnan SV","year":"2017","journal-title":"Blood"},{"key":"e_1_2_9_73_1","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/753407"},{"key":"e_1_2_9_74_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-793869"},{"key":"e_1_2_9_75_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1871"},{"key":"e_1_2_9_76_1","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2018.1544240"},{"key":"e_1_2_9_77_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-018-0346-9"},{"key":"e_1_2_9_78_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02722"},{"key":"e_1_2_9_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2020.101141"},{"key":"e_1_2_9_80_1","doi-asserted-by":"publisher","DOI":"10.3109\/08923973.2016.1153110"},{"key":"e_1_2_9_81_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2014.12.003"},{"key":"e_1_2_9_82_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.matbio.2011.10.001"},{"key":"e_1_2_9_83_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molonc.2013.12.001"},{"key":"e_1_2_9_84_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-01-761643"},{"key":"e_1_2_9_85_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocit.2014.11.001"},{"key":"e_1_2_9_86_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2362.2012.02679.x"},{"key":"e_1_2_9_87_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aau7746"},{"key":"e_1_2_9_88_1","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1158\/2159-8290.CD-RW2019-051","article-title":"Gprc5d car T\u2010cell therapy has antitumor activity in multiple myeloma","volume":"9","year":"2019","journal-title":"Cancer Discov"},{"key":"e_1_2_9_89_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2018.05.001"},{"key":"e_1_2_9_90_1","first-page":"A49","article-title":"New gene\u2010editing strategy for allogeneic NKG2D\u2010CAR T cell production","volume":"30","author":"Serna J","year":"2019","journal-title":"Hum Gene Ther"},{"key":"e_1_2_9_91_1","doi-asserted-by":"publisher","DOI":"10.1093\/jrr\/rry005"},{"key":"e_1_2_9_92_1","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-18-0307"},{"key":"e_1_2_9_93_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-04-493361"},{"key":"e_1_2_9_94_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V122.21.142.142"},{"key":"e_1_2_9_95_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-117974"},{"key":"e_1_2_9_96_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-04-017061"},{"key":"e_1_2_9_97_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI86000"},{"key":"e_1_2_9_98_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2595"},{"key":"e_1_2_9_99_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2018.11.002"},{"key":"e_1_2_9_100_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1819745116"},{"key":"e_1_2_9_101_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2018.03.002"},{"key":"e_1_2_9_102_1","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_200889"},{"key":"e_1_2_9_103_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.5702.5702"},{"key":"e_1_2_9_104_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.08.002"},{"key":"e_1_2_9_105_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-10-535088"},{"key":"e_1_2_9_106_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01821"},{"key":"e_1_2_9_107_1","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2019.1624158"},{"key":"e_1_2_9_108_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2019.1586539"},{"key":"e_1_2_9_109_1","doi-asserted-by":"crossref","first-page":"5671","DOI":"10.1158\/1538-7445.AM2017-5671","article-title":"AFM26\u2010A novel CD16A\u2010directed bispecific TandAb targeting BCMA for multiple myeloma","volume":"77","author":"Gantke T","year":"2017","journal-title":"Cancer Res"},{"key":"e_1_2_9_110_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.388"},{"key":"e_1_2_9_111_1","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2019.1641196"}],"container-title":["Scandinavian Journal of Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/sji.12910","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/sji.12910","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/sji.12910","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T08:59:22Z","timestamp":1693299562000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/sji.12910"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,17]]},"references-count":110,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["10.1111\/sji.12910"],"URL":"https:\/\/doi.org\/10.1111\/sji.12910","archive":["Portico"],"relation":{},"ISSN":["0300-9475","1365-3083"],"issn-type":[{"value":"0300-9475","type":"print"},{"value":"1365-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,17]]},"assertion":[{"value":"2019-12-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-19","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e12910"}}